Sarah A. Alwardt, PhD | Authors


Underused Next-Generation Sequence Testing Revealed in MYLUNG Consortium Study

June 15, 2021

Results from the first phase of the broad, collaborative MYLUNG research study in lung cancer provide a close-up look at current biomarker testing rates and turnaround times for patients treated in community practices within The US Oncology Network.

How to Leverage Real-World Data as COVID-19 Transforms Clinical Trials

October 27, 2020

Due to efforts to reduce exposure to the coronavirus, oncology patient volumes initially decreased, treatment regimens were disrupted or altered, and new cancer diagnoses also slowed. This affected not only patient care, but also clinical trials.